ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
121.341,13
0,74%
S&P 500
5.464,62
-0,16%
US Dollar vs BRL
5,4321
-0,20%
Bitcoin
64.450,43
0,32%
Brent Oil
84,39
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. HUTCHMED China Limited (HCM)

  7. HUTCHMED China Limited (HCM) Notícias

HCM HUTCHMED China Limited

17,93
0,67 (3,88%)
21 Jun 2024 - Fechado
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
HUTCHMED China Limited HCM NASDAQ Recibo de Depósito
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,67 3,88% 17,93 21:00:00
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
17,43 17,43 18,15 17,93 17,26
mais cotações »

Notícias Recentes

Data Hora Fonte Título
21/06/202417:00GLOBEHUTCHMED Announces European Commission Approval for..
16/06/202421:00GLOBEHUTCHMED Highlights Publication of Phase III ESLIM-01..
06/06/202421:00GLOBEHUTCHMED Initiates Phase I Trial of Menin Inhibitor HMPL-506..
02/06/202421:00GLOBEHUTCHMED Highlights Publication of Phase III FRUTIGA Results..
23/05/202421:00GLOBEHUTCHMED Highlights Presentations at the 2024 ASCO Annual..
17/05/202411:00GLOBEHUTCHMED announces retirement of Chairman, appointment of..
16/05/202421:00GLOBEHUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and..
13/05/202421:00GLOBEHUTCHMED Initiates Phase II/III Trial of the Combination of..
08/05/202405:30GLOBEHUTCHMED Announces Appointment of Independent Non-executive..
26/04/202409:30GLOBEHUTCHMED Announces Positive CHMP Opinion for Fruquintinib in..
05/04/202405:30GLOBEHUTCHMED Highlights Data to be Presented at..
02/04/202401:30GLOBEHUTCHMED and Innovent Jointly Announce NDA Acceptance in..
27/03/202421:00GLOBEHUTCHMED Announces Savolitinib sNDA Accepted in China for..
21/03/202421:00GLOBEHUTCHMED Initiates Registration Stage of the ESLIM-02 Phase..
28/02/202408:30GLOBEHUTCHMED Reports 2023 Full Year Results and Provides..
06/02/202421:00GLOBEHUTCHMED Highlights Presentation of Phase III Data on..
02/02/202405:30GLOBEHUTCHMED Announces that Inmagene Exercises Option to License..
01/02/202405:30GLOBEHUTCHMED to Announce 2023 Final Results
30/01/202401:53GLOBEHUTCHMED Receives ELUNATE® (fruquintinib) Marketing Approval..
11/01/202404:00RNSNONHutchmed (China) Limited Sovleplenib NDA Granted Priority..
10/01/202421:00GLOBEHUTCHMED Announces NDA Acceptance in China for Sovleplenib..
13/12/202304:00RNSNONHutchmed (China) Limited Completed Enrollment of Phase..
13/12/202301:30GLOBEHUTCHMED Announces Continued Inclusion of ELUNATE®..
12/12/202321:00GLOBEHUTCHMED Announces that it has Completed Enrollment of a..
01/12/202304:00RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
30/11/202321:00GLOBEHUTCHMED Highlights Clinical Data to be Presented at 2023..
10/11/202310:35GLOBEDeutsche Bank ADR Investor Conference: Presentations Now..
08/11/202321:11GLOBEHUTCHMED Announces that Takeda Receives U.S. FDA Approval of..
01/11/202309:35GLOBEInternational companies to host live webcasts at Deutsche..
16/10/202305:30RNSNONHutchmed (China) Limited Clinical Data to be Presented at..
29/09/202305:30RNSNONHutchmed (China) Limited NDA Submission for Fruquintinib in..
12/09/202305:30RNSNONHutchmed (China) Limited Phase IIIb Savolitinib Results at..
12/09/202303:00RNSNONHutchmed (China) Limited Patient Enrollment Completed for..
11/09/202321:00GLOBEHUTCHMED Completes Patient Enrollment of a Bridging Study of..
29/08/202303:00RNSNONHutchmed (China) Limited BTD in China for Savolitinib for..
28/08/202321:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
20/08/202321:00GLOBEHUTCHMED Announces that the Sovleplenib Phase III ESLIM-01..
31/07/202308:41GLOBEHUTCHMED Reports 2023 Interim Results and Provides..
20/07/202303:00RNSNONHutchmed (China) Limited Breakthrough Therapy Designation..
19/07/202321:00GLOBEHUTCHMED Receives Breakthrough Therapy Designation in China..
13/07/202305:30GLOBEHUTCHMED Announces Changes to Board of Directors and..
10/07/202303:00RNSNONHutchmed (China) Limited Phase 1 Study of HMPL-415 Initiated
09/07/202321:00GLOBEHUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor..
26/06/202305:30GLOBEHUTCHMED to Announce 2023 Half-Year Financial Results

Seu Histórico Recente

NASDAQ
HCM
HUTCHMED China
COIN
OXENBTC
Oxen
BIT
P1Z8J6
NLBNPIT1Z8J6 20240918 5200
USOTC
BYLTF
Baylin Technologies (PK)
BIT
IRE
Iren
TSXV
GTM.P
G2M Cap
BIT
P1KOE3
BNP Paribas Issuance
USOTC
ATZAF
Aritzia (PK)
BOV
ALPA4M
ALPARGATAS PN
TG
XTIP
Xtrackers II
USOTC
DYMDF
Diamyd Med AB (GM)
EU
V3EA
Vanguard Funds
BIT
UC4PPM
Unicredit Bank
LSE
EQLS
Equals
BIT
F15813
Vontobel Financial Produ...
UNSW3
PLXETH
PlayX Coin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados